What’s the problem?
March 4, 2011 – The FDA has issued a warning about the risk of development of cleft lip and/or cleft palate (oral clefts) in babies born to women treated with the anticonvulsant drug Topamax (topiramate) while pregnant. Because of new conclusive evidence about this risk, the administration has required Topamax to be placed in Pregnancy Category D, which indicates there is direct evidence of birth defects based on human data.
The FDA strongly advises pregnant women and women of childbearing potential to discuss other treatment options with their doctor before taking Topamax. Women taking topiramate should consult their doctor immediately if they are pregnant or planning to become pregnant. Additionally, women who become pregnant while taking Topamax should talk to their doctor about registering with the North American Antiepileptic Drug Pregnancy Registry, a group that collects information about outcomes in infants born to women treated with antiepileptic drugs during pregnancy.
Topamax Birth Defects Update 7/19/12: A recently-published study, based on more than a decade’s worth of data, has confirmed prior research which identified a strong link between Topamax and oral cleft birth defects. This risk is greatest when expecting mothers take Topamax during their first trimester of pregnancy, a time when many women may still be unaware they are pregnant.
Do I have a Topamax Lawsuit?
The Pharmaceutical Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Topamax lawsuits. We are handling individual litigation nationwide and currently accepting new birth defect cases in all 50 states.
If your child or other loved one was born with a birth defect after the mother used Topamax, you should contact our law firm immediately. You may be entitled to compensation by filing a suit and we can help.